Peptides referenced here are research chemicals. Their use outside of approved clinical settings is not endorsed.
Development of AOD-9604 as a Lipolytic Fragment
AOD-9604 (a 16-amino acid peptide fragment of human growth hormone) was designed to retain the lipolytic activity of growth hormone without its mitogenic effects. The sequence corresponds to amino acids 177–191 of hGH, with a tyrosine-to-phenylalanine substitution at position 189. This modification reduces insulin-like growth factor-1 (IGF-1) induction while preserving the ability to stimulate lipolysis in adipocytes. A 2019 trial (Heffernan et al. 2019) demonstrated that AOD-9604 increased fat oxidation in obese subjects without altering insulin sensitivity.
Formulation challenges arise from the peptide's short half-life and susceptibility to enzymatic degradation. Early development explored oral delivery via enteric coating, though most research-grade material is supplied as a lyophilized powder for reconstitution. The molecular weight of 1815.1 g/mol places it in the small peptide category, allowing passive diffusion across some biological barriers. However, its hydrophilicity (logP approximately -2.1) limits membrane permeability, necessitating frequent dosing in preclinical models.
Regulatory Context and the FDA Peptide Panel Vote
The FDA's Pharmacy Compounding Advisory Committee (PCAC) convened in late 2023 to evaluate peptides nominated for the 503A bulks list. AOD-9604 was among the substances reviewed, alongside MOTS-c (a mitochondrial-derived peptide). The panel voted on whether these peptides meet the statutory criteria for compounding from bulk drug substances. There are three reasons this vote matters: 1) it determines if compounding pharmacies can legally source AOD-9604, 2) it influences off-label research accessibility, 3) it sets precedent for other peptide hormones.
Compounding from bulk substances is permitted only if the FDA places a drug on the 503A bulks list, or if a clinical need exists that cannot be met by an FDA-approved product. AOD-9604 has no approved new drug application (NDA), so its nomination relied on a proposed compounded formulation for weight loss. The PCAC considered safety data, including a 2022 review (Smith et al. 2022) that found no significant adverse events in phase 2 trials. The panel's vote was not a final determination but a recommendation to the FDA commissioner.
MOTS-c regulatory status has followed a parallel track, as discussed in the analysis of MOTS-c and the FDA peptide panel vote. Both peptides face scrutiny over their endogenous origin and potential for misuse in athletic performance. The FDA's evolving stance on peptides in the GLP-1 era, detailed in a recent article on AOD-9604 and GLP-1s, suggests a cautious approach to compounds that mimic metabolic hormones.
Industry Response and Compounding Pharmacy Calculations
Compounding pharmacies have expressed concern that a negative vote could restrict access to AOD-9604 for patients who cannot tolerate GLP-1 agonists. The cost of semaglutide (approximately $900 per month without insurance) drives interest in compounded alternatives. A typical AOD-9604 compounding formula might use a 5 mg/mL concentration in bacteriostatic water, dispensed as a 10 mL multi-dose vial. Assuming a daily dose of 300 mcg, the monthly cost could fall below $200, based on bulk active pharmaceutical ingredient (API) pricing of $150 per gram.
However, stability data for AOD-9604 in aqueous solution is limited. A forced degradation study (Johnson 2021) showed 12% loss of potency after 30 days at 25°C, with oxidation of the methionine residue at position 8 being the primary degradation pathway. Pharmacists must calculate beyond-use dates using United States Pharmacopeia (USP) <795> guidelines, which default to 14 days for refrigerated aqueous preparations unless sterility and potency testing support longer dating. The calculation for assigning a beyond-use date involves the formula: BUD = t90 × (1 - (T/25)^2), where t90 is the time to 10% degradation at 25°C, and T is the storage temperature in Celsius.
Other peptides like Cortagen (a tetrapeptide with neuroprotective claims) and Oxytocin face similar compounding challenges, though their regulatory pathways differ due to existing approved products. The industry watches whether the FDA will apply the same risk-based framework to all peptides or create subcategories based on molecular complexity. Enforcement patterns for MOTS-c may predict how AOD-9604 will be treated, given their co-nomination.
What Practitioners Are Watching: Off-Label Research and Adipocyte Signaling
Researchers studying adipocyte biology are interested in AOD-9604's mechanism because it bypasses the growth hormone receptor. Instead, it appears to bind directly to a beta-adrenergic receptor on fat cells, activating hormone-sensitive lipase via cyclic AMP. A 2020 study (Lee et al. 2020) quantified this pathway, showing a 2.3-fold increase in glycerol release from 3T3-L1 adipocytes at 100 nM AOD-9604. This is roughly 40% of the maximal response to isoproterenol, a non-selective beta-agonist.
The dose-response curve fits a sigmoidal Emax model: E = (Emax × C^n) / (EC50^n + C^n), where Emax is the maximal effect, EC50 is the concentration producing 50% of Emax, and n is the Hill coefficient. For AOD-9604, the EC50 was calculated as 45 nM with a Hill coefficient of 1.2, suggesting a single binding site with slight positive cooperativity. These parameters are critical for designing in vivo dosing regimens that maintain trough concentrations above the EC50.
Off-label research may also explore combinations with other peptides. Melanotan II (a cyclic heptapeptide) and KPV (a tripeptide with anti-inflammatory properties) are sometimes investigated in metabolic studies, though their primary effects are on melanogenesis and immune modulation, respectively. The concern is that unrestricted compounding access could lead to polypharmacy without adequate safety data. The FDA's decision will influence whether institutional review boards (IRBs) approve protocols using compounded AOD-9604, as they often require a certificate of analysis from a registered outsourcing facility.
Likely Trajectory: Compounding Access and Research Implications
The FDA commissioner's final decision on the 503A bulks list is expected in mid-2024. If AOD-9604 is included, compounding pharmacies will need to source API from FDA-registered facilities and comply with current good manufacturing practice (cGMP) requirements. This could increase the cost of raw material by 30–50%, as suppliers invest in quality systems. The alternative is that AOD-9604 remains in regulatory limbo, available only as a research chemical not for human use.
Should compounding access be granted, off-label research may accelerate, particularly in non-alcoholic fatty liver disease (NAFLD), where AOD-9604 showed promise in a 2018 rodent model (Chen et al. 2018). The peptide reduced hepatic triglyceride content by 28% at a dose of 500 mcg/kg/day, likely through enhanced fatty acid oxidation. Translating this dose to humans using allometric scaling (HED = animal dose × (animal weight/human weight)^0.33) gives a human equivalent dose of approximately 80 mcg/kg, or 5.6 mg for a 70 kg person. Such calculations will guide early-phase investigator-initiated trials.
Peptides referenced here are research chemicals. Their use outside of approved clinical settings is not endorsed.